4.5 Article

Integrated HIV testing, prevention, and treatment intervention for key populations in India: a cluster-randomised trial

期刊

LANCET HIV
卷 6, 期 5, 页码 E283-E296

出版社

ELSEVIER INC
DOI: 10.1016/S2352-3018(19)30034-7

关键词

-

资金

  1. US National Institutes of Health [R01DA032059, R01MH089266, K24DA035684, T32AI102623, F31DA044046]
  2. Johns Hopkins University Centre for AIDS Research [P30AI094189]
  3. Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  4. Elton John AIDS Foundation
  5. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000361] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Background To achieve reductions in HIV incidence, we need strategies to engage key population at risk for HIV in low-income and middle-income countries. We evaluated the effectiveness of integrated care centres in India that provided single-venue HIV testing, prevention, and treatment services for people who inject drugs (PWID) and men who have sex with men (MSM). Methods We did baseline respondent-driven sampling surveys in 27 sites across India, and selected 22 of these (12 PWID and ten MSM) for a cluster randomised trial on the basis of high HIV prevalence and logistical considerations. We used stratified (by PWID and MSM), restricted randomisation to allocate sites to either the integrated care intervention or usual care (11 sites per group). We implemented integrated care centres in 11 cities (six PWID integrated care centres embedded within opioid agonist treatment centres and five MSM centres within government-sponsored health services), with a single integrated care centre per city in all but one city. After a 2-year intervention phase, we did respondent-driven sampling evaluation surveys of target population members who were aged 18 years or older at all sites. The primary outcome was self-reported HIV testing in the previous 12 months (recent testing), determined via the evaluation survey. We used a biometric identification system to estimate integrated care centre exposure (visited an integrated care centre at least once) among evaluation survey participants at intervention sites. This trial is registered with ClinicalTrials. gov, number NCT01686750. Findings Between Oct 1, 2012, and Dec 19, 2013, we recruited 11 993 PWID and 9997 MSM in the baseline survey and, between Aug, 1 2016, and May 27, 2017, surveyed 11 721 PWID and 10 005 MSM in the evaluation survey using respondent-driven sampling, across the 22 trial sites. During the intervention phase, integrated care centres provided HIV testing for 14 698 unique clients (7630 PWID and 7068 MSM). In the primary population-level analysis, recent HIV testing was 31% higher at integrated care centres than at usual care sites (adjusted prevalence ratio [PR] 1 . 31, 95% CI 0 . 95-1 . 81, p= 0 . 09). Among survey participants at intervention sites, integrated care centre exposure was lower than expected (median exposure 40% at PWID sites and 24% at MSM sites). In intervention sites, survey participants who visited an integrated care centre were more likely to report recent HIV testing than were participants who had not (adjusted [PR] 1.31, 95% CI 0.95-1.81 p=0.09). Interpretation Although integrated care centres increased HIV testing among visitors, our low exposure findings suggest that the scale-up of a single integrated care centre in most cities was insufficient to serve the large PWID and MSM populations. Future work should address the use of population size estimates to guide the dose of combination HIV interventions targeting key populations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Status in Decedents Undergoing Forensic Postmortem Examination in Maryland, May 24 to June 30, 2020

Keri N. Althoff, Oliver Laeyendecker, Rong Li, Sally B. Coburn, Ethan Klock, Owen R. Baker, Thomas C. Quinn, Jeffrey Michael, Wendy C. Shields, Johnathon Ehsani, F. Dennis Thomas, Lindsey A. Graham, Zabiullah Ali, Yukari C. Manabe, Ling Li

Summary: The seroprevalence of SARS-CoV-2 antibodies among decedents undergoing forensic postmortem examination in Maryland was 10% in June. Decedents of motor vehicle crashes showed similar seroprevalence compared to those with a natural death, including individuals with SARS-CoV-2 infection, suggesting they may be a sentinel surveillance population.

OPEN FORUM INFECTIOUS DISEASES (2021)

Article Immunology

Validation of the Asante HIV-1 Rapid Recency Assay for Detection of Recent HIV-1 Infections in Uganda

Ronald Moses Galiwango, Charles Ssuuna, Pontiano Kaleebu, Godfrey Kigozi, Joseph Kagaayi, Gertrude Nakigozi, Steven James Reynolds, Tom Lutalo, Edward Nelson Kankaka, John Bosco Wasswa, Sarah N. Kalibbala, Aminah N. Kigozi, Christine Watera, Julia Ejang, Anthony Ndyanabo, Aggrey J. Anok, Deogratius Ssemwanga, Freddie M. Kibengo, Thomas C. Quinn, Mary Grabowski, Larry W. Chang, Maria Wawer, Ronald Gray, Oliver Laeyendecker, David Serwadda

Summary: Point of care rapid recency testing for HIV-1 in Uganda showed low sensitivity and high specificity, with substantial interlaboratory variability. Additional assessment in different settings is needed to evaluate test utility.

AIDS RESEARCH AND HUMAN RETROVIRUSES (2021)

Article Biology

Regression with interval-censored covariates: Application to cross-sectional incidence estimation

Doug Morrison, Oliver Laeyendecker, Ron Brookmeyer

Summary: The study introduces a method for generalized linear regression with interval-censored covariates, which indirectly infers the distribution of the covariate of interest compared to other conventional approaches. The proposed method shows less bias but slight increases in standard error when compared to midpoint analysis and uniform imputation methods.

BIOMETRICS (2022)

Article Immunology

The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)

Bezawit A. Woldemeskel, Andrew H. Karaba, Caroline C. Garliss, Evan J. Beck, Kristy H. Wang, Oliver Laeyendecker, Andrea L. Cox, Joel N. Blankson

Summary: Past studies have shown that some vaccines do not elicit optimal responses in individuals living with HIV. However, this study demonstrates that the BNT162b2 vaccine induces robust immune responses in these patients comparable to those in healthy donors.

CLINICAL INFECTIOUS DISEASES (2022)

Article Infectious Diseases

Severe Acute Respiratory Syndrome Coronavirus-2 seroprevalence in South-Central Uganda, during 2019-2021

Charles Ssuuna, Ronald Moses Galiwango, Edward Nelson Kankaka, Joseph Kagaayi, Anthony Ndyanabo, Godfrey Kigozi, Gertrude Nakigozi, Tom Lutalo, Robert Ssekubugu, John Bosco Wasswa, Anthony Mayinja, Martina Cathy Nakibuuka, Samiri Jamiru, John Baptist Oketch, Edward Muwanga, Larry William Chang, Mary Kate Grabowski, Maria Wawer, Ronald Gray, Mark Anderson, Michael Stec, Gavin Cloherty, Oliver Laeyendecker, Steven James Reynolds, Thomas C. Quinn, David Serwadda

Summary: The study found a high seroprevalence of antibodies to SARS-CoV-2 among HCW in South-Central Uganda, with a rate of 26.7%. Additionally, individuals presenting with specific COVID-19 like symptoms had a seroprevalence rate of 15.6%. Prior to the first confirmed COVID-19 case in Uganda, 2.3% of collected plasma specimens exhibited reactivity.

BMC INFECTIOUS DISEASES (2022)

Article Microbiology

Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department

Evan J. Beck, Yu-Hsiang Hsieh, Reinaldo E. Fernandez, Gaby Dashler, Emily R. Egbert, Shawn A. Truelove, Caroline Garliss, Richard Wang, Evan M. Bloch, Ruchee Shrestha, Joel Blankson, Andrea L. Cox, Yukari C. Manabe, Thomas Kickler, Richard E. Rothman, Andrew D. Redd, Aaron A. R. Tobian, Aaron M. Milstone, Thomas C. Quinn, Oliver Laeyendecker

Summary: Emergency departments can be used as surveillance sites for infectious diseases. This study aimed to determine the burden of SARS-CoV-2 infection and monitor the prevalence of COVID-19 vaccination among patients attending an urban ED in Baltimore City. A testing algorithm was developed to differentiate between previously infected, vaccinated, and unexposed individuals using antibody assays. The study found significant differences in disease burden and vaccination coverage based on sex, race, and ethnicity.

JOURNAL OF CLINICAL MICROBIOLOGY (2022)

Article Multidisciplinary Sciences

A highly virulent variant of HIV-1 circulating in the Netherlands

Chris Wymant, Daniela Bezemer, Francois Blanquart, Luca Ferretti, Astrid Gall, Matthew Hall, Tanya Golubchik, Margreet Bakker, Swee Hoe Ong, Lele Zhao, David Bonsall, Mariateresa de Cesare, George MacIntyre-Cockett, Lucie Abeler-Doerner, Jan Albert, Norbert Bannert, Jacques Fellay, M. Kate Grabowski, Barbara Gunsenheimer-Bartmeyer, Huldrych F. Gunthard, Pia Kivela, Roger D. Kouyos, Oliver Laeyendecker, Laurence Meyer, Kholoud Porter, Matti Ristola, Ard van Sighem, Ben Berkhout, Paul Kellam, Marion Cornelissen, Peter Reiss, Christophe Fraser

Summary: A highly virulent variant of subtype-B HIV-1 was discovered in the Netherlands. Infected individuals with this variant had significantly higher viral loads and faster decline in CD4 cells compared to other subtype-B strains. The increased virulence is attributed to the viral strain, and the variant emerged in the 1990s with increased transmissibility and an unfamiliar molecular mechanism of virulence.

SCIENCE (2022)

Article Medicine, Research & Experimental

Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection

Han-Sol Park, Janna R. Shapiro, Ioannis Sitaras, Bezawit A. Woldemeskel, Caroline C. Garliss, Amanda Dziedzic, Jaiprasath Sachithanandham, Anne E. Jedlicka, Christopher A. Caputo, Kimberly E. Rousseau, Manjusha Thakar, San Suwanmanee, Pricila Hauk, Lateef Aliyu, Natalia Majewska, Sushmita Koley, Bela Patel, Patrick Broderick, Giselle Mosnaim, Sonya L. Heath, Emily S. Spivak, Aarthi Shenoy, Evan M. Bloch, Thomas J. Gniadek, Shmuel Shoham, Arturo Casadevall, Daniel Hanley, Andrea L. Cox, Oliver Laeyendecker, Michael J. Betenbaugh, Steven M. Cramer, Heba H. Mostafa, Andrew Pekosz, Joel N. Blankson, Sabra L. Klein, Aaron A. R. Tobian, David Sullivan, Kelly A. Gebo

Summary: Benchmarks for protective immunity from infection or severe disease after SARS-CoV-2 vaccination are still being defined. In this study, the researchers compared different immune responses and viral variants in different groups, including vaccinated individuals and symptomatic patients. The findings showed that neutralizing antibody levels declined over time and were lower against the Alpha variant. Partially and fully vaccinated patients had lower neutralizing antibody levels against the parent virus compared to healthy controls. The study also found that neutralization activity against the Alpha variant was lower in the partially and fully vaccinated infected patients. Parent virus neutralization was identified as a predictive factor for breakthrough infections with the Alpha variant.

JCI INSIGHT (2022)

Article Microbiology

Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8+ T-Cell Epitopes Identified in COVID-19 Convalescent Individuals

Andrew D. Redd, Alessandra Nardin, Hassen Kared, Evan M. Bloch, Brian Abel, Andrew Pekosz, Oliver Laeyendecker, Michael Fehlings, Thomas C. Quinn, Aaron A. R. Tobian

Summary: This study found that the newly identified Omicron variant of concern contains only one mutation in a low-prevalence epitope targeted by CD8(+) T cells, suggesting that the T-cell immune response in previously infected and vaccinated individuals should still be effective against Omicron.
Letter Immunology

Could rapid test reader maximize the benefits to the HIV self-tester?

Pachamuthu Balakrishnan, A. S. Smiline Girija, Iyanar Kannan, Ramachandran Vignesh, Esaki M. Shankar, Sree T. Sucharitha

INDIAN JOURNAL OF MEDICAL MICROBIOLOGY (2023)

Article Medicine, General & Internal

Plasma interleukin-7 correlation with human immunodeficiency virus RNA and CD4+T cell counts, and interleukin-5 with circulating hepatitis B virus DNA may have implications in viral control

Jaisheela Vimali, Yean Kong Yong, Amudhan Murugesan, Kumaran Vishnupriya, Rajeev Ashwin, Evangeline Ann Daniel, Pachamuthu Balakrishnan, Sivadoss Raju, Mohamed Rosmawati, Vijayakumar Velu, Marie Larsson, Esaki M. Shankar

Summary: Chronic viral infections lead to cytokine perturbations, which play a key role in the development of the disease. This study found differential cytokine profiles in different infection groups, and cytokine levels were positively correlated with viral loads and liver parameters. Furthermore, IL-5 and IL-7 were identified as cytokines that are closely related to viral control in HBV and HIV infections, respectively.

FRONTIERS IN MEDICINE (2022)

Article Immunology

Surrogate Biomarkers of Disease Progression in Human Pegivirus Seropositive Human Immunodeficiency Virus-Infected Individuals

Jaisheela Vimali, Yean K. Yong, Amudhan Murugesan, Rajeev Ashwin, Pachamuthu Balakrishnan, Sivadoss Raju, Vijayakumar Velu, Marie Larsson, Esaki M. Shankar

Summary: Scientific observations suggest that human pegivirus (HPgV) has a positive impact on the progression of HIV disease, potentially reducing HIV viral load and hepatic injury.

VIRAL IMMUNOLOGY (2023)

Article Microbiology

Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment

Andrew H. Karaba, Trevor S. Johnston, Evan Beck, Oliver Laeyendecker, Andrea L. Cox, Sabra L. Klein, David J. Sullivan

Summary: The relevance of preexisting immunity to the four endemic human coronaviruses in the first week of COVID-19 illness on the outcome of COVID-19 progression stems from the high prevalence of the ehCoV and SARS-CoV-2 coronaviruses. The question has been raised of whether therapeutic convalescent plasma or control plasma containing ehCoV antibodies might alter the outcome of COVID-19 progression to hospitalization.
Article Microbiology

COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial

Feben Habtehyimer, Xianming Zhu, Andrew D. Redd, Kelly A. Gebo, Alison G. Abraham, Eshan U. Patel, Oliver Laeyendecker, Thomas J. Gniadek, Reinaldo E. Fernandez, Owen R. Baker, Malathi Ram, Edward R. Cachay, Judith S. Currier, Yuriko Fukuta, Jonathan M. Gerber, Sonya L. Heath, Barry Meisenberg, Moises A. Huaman, Adam C. Levine, Aarthi Shenoy, Shweta Anjan, Janis E. Blair, Daniel Cruser, Donald N. Forthal, Laura L. Hammitt, Seble Kassaye, Giselle S. Mosnaim, Bela Patel, James H. Paxton, Jay S. Raval, Catherine G. Sutcliffe, Matthew Abinante, Kevin S. Oei, Valerie Cluzet, Marie Elena Cordisco, Benjamin Greenblatt, William Rausch, David Shade, Amy L. Gawad, Sabra L. Klein, Andrew Pekosz, Shmuel Shoham, Arturo Casadevall, Evan M. Bloch, Daniel Hanley, Aaron A. R. Tobian, David J. Sullivan

Summary: Early convalescent plasma transfusion can reduce the risk of hospitalization for COVID-19 patients, possibly by decreasing IL-6 levels and reducing disease severity.

MICROBIOLOGY SPECTRUM (2023)

Article Microbiology

Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers

Eshan U. Patel, Evan M. Bloch, William Clarke, Yu-Hsiang Hsieh, Denali Boon, Yolanda Eby, Reinaldo E. Fernandez, Owen R. Baker, Morgan Keruly, Charles S. Kirby, Ethan Klock, Kirsten Littlefield, Jernelle Miller, Haley A. Schmidt, Philip Sullivan, Estelle Piwowar-Manning, Ruchee Shrestha, Andrew D. Redd, Richard E. Rothman, David Sullivan, Shmuel Shoham, Arturo Casadevall, Thomas C. Quinn, Andrew Pekosz, Aaron A. R. Tobian, Oliver Laeyendecker

Summary: Accurate serological assays are crucial for detecting SARS-CoV-2 antibodies, but commercial EIAs may not always accurately detect high nAb titers in individuals, indicating the limitations of current diagnostic methods for COVID-19 convalescent plasma donation.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

暂无数据